FDA hands Crestor a fighting chance

In the battle of the cholesterol meds, Crestor just got a new weapon. The FDA approved AstraZeneca's application to market the drug not just for lowering cholesterol, but to treat hardening of the arteries, too. It's the first statin to win approval for that indication.

It's an important coup for AstraZeneca, which has been looking for an edge for Crestor--a late entry onto the statin field. As you know, those efforts were compromised earlier this week by research showing the drug didn't alleviate heart failure. And last week, AstraZeneca announced it was facing a generic challenge to Crestor's patents.

- check out the release from AstraZeneca
- read the report from The Times

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.